Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DOTA-STR-17126
- Development stage
- Unknown
- Lead developer
- Stingray Bio
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Peptides
- Administration
- Intravenous
01
Overview
DOTA-STR-17126 is a novel theranostic radiopharmaceutical consisting of a DOTA-chelator conjugated to a peptide antagonist (STR-17126) that targets the **Gastrin-Releasing Peptide Receptor (GRPR)**. GRPR is highly expressed in several solid tumors, including metastatic prostate and breast cancers, making it an attractive target for precision oncology. The agent is developed as a theranostic pair: **[68Ga]Ga-DOTA-STR-17126** is utilized for Positron Emission Tomography (PET) imaging to identify and quantify GRPR-positive lesions, while **[177Lu]Lu-DOTA-STR-17126** is intended for Targeted Radionuclide Therapy (TRT) to deliver cytotoxic radiation directly to the tumor cells. Developed by **Stingray Bio** in collaboration with the **Icon Cancer Foundation**, the compound is currently undergoing first-in-human exploratory imaging studies in Australia to evaluate its safety, biodistribution, and dosimetry in patients with advanced or metastatic malignancies.
- Other names
- [68Ga]Ga-DOTA-STR-17126[177Lu]Lu-DOTA-STR-1712668Ga-DOTA-STR-17126177Lu-DOTA-STR-17126
02
Targets
GRPR (Gastrin-releasing peptide receptor)
Beyond the preview
Go deeper on DOTA-STR-17126.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DOTA-STR-17126.